As we mentioned above, Wegovy is a semaglutide, or a GLP-1 receptor agonist
In a note in August, Goldman Sachs analysts forecasted that pills will capture a 24% share or around $22 billion of the 2030 global weight loss drug market, which they expect to be worth $95 billion in total
Resmetirom is the first FDA-approved therapy for MASLD with significant or advanced fibrosis, but several other therapies, including incretin-based therapies and SGLT-2i, can be considered according to the presence of comorbidities such as excess weight or T2DM
Its typical role is for people already taking it for diabetes who get some weight benefit as a bonus, rather than people seeking maximum weight reduction
controlled human efficacy evidence is lacking and individual results vary
Studies of the kallikrein-kinin system in patients with sickle cell anemia